PF-219,061
PF-219,061 je potentan i visoko selektivan agonist dopaminskog D3 receptora.[1][2] Ovaj materijal razvija kompanija Pfizer kao potencijalni lek za tretiranje impotencije žena.[3][4]
IUPAC ime | |
---|---|
(R)-3-(4-propilmorfolin-2-il)fenol | |
Klinički podaci | |
Način primene | Nazalno |
Identifikatori | |
CAS broj | 710654-74-3 |
ATC kod | none |
PubChem | CID 9794475 |
Hemijski podaci | |
Formula | C13H19NO2 |
Molarna masa | 221,295 g/mol |
|
Reference
уреди- ^ Blagg, Julian; Allerton, Charlotte M.N.; Batchelor, David V.J.; Baxter, Andrew D.; Burring, Denise J.; Carr, Christopher L.; Cook, Andrew S.; Nichols, Carly L.; Phipps, Joanne; Sanderson, Vivienne G.; Verrier, Hugh; Wong, Stephen (2007-12-15). „Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route”. Bioorganic & Medicinal Chemistry Letters. 17 (24): 6691—6. PMID 17976986. doi:10.1016/j.bmcl.2007.10.059.
- ^ Brioni, Jorge D.; Moreland, Robert B. (2006). „Dopamine D4 receptors and the regulation of penile erection”. Drug Discovery Today: Therapeutic Strategies. 3 (4): 599—604. doi:10.1016/j.ddstr.2006.10.006.
- ^ Van Der Graaf et al. SELECTIVE DOPAMINE D3 RECEPTOR AGONISTS FOR THE TREATMENT OF SEXUAL DYSFUNCTION. WIPO Patent WO/2003/051370, granted to Pfizer[мртва веза].
- ^ Attkins, N. J.; Heatherington, A. C.; Phipps, J.; Verrier, H.; Huyghe, I. (јул 2009). „Predictability of intranasal pharmacokinetics in man using pre-clinical pharmacokinetic data with a dopamine 3 receptor agonist, PF-219061”. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 39 (7): 523—33. PMID 19480558. S2CID 26474660. doi:10.1080/00498250902893775.
Vidi još
уредиSpoljašnje veze
уреди
Molimo Vas, obratite pažnju na važno upozorenje u vezi sa temama iz oblasti medicine (zdravlja). |